Applied dna to increase covid-19 surveillance testing utility for its linea™ covid-19 assay kits through expanded use of robotic automation

Stony brook, n.y.--(business wire)---- $apdn #covid19--applied dna sciences, inc. (nasdaq: apdn) (“applied dna” or the "company"), a leader in polymerase chain reaction (pcr)-based dna manufacturing that enables diagnostics in vitro, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, today announced that it plans to boost its covid-19 testing capacity at applied dna clinical laboratories, llc (“adcl”), its wholly-owned subsidiary, to
APDN Ratings Summary
APDN Quant Ranking